[3][4] Board members, spokespeople, and a panel of experts work to change drug policy through public testimony, lectures, op-eds, media appearances, research, and support for legislation individually and as part of larger coalitions.
[5] Testimony has been given to legislators in Alabama, California, Colorado, Connecticut, Delaware, Hawaii, Illinois, Kansas, Maryland, Massachusetts, Montana, New Hampshire, New Jersey, New York, Oregon, Pennsylvania, Rhode Island, South Carolina, Texas, Vermont, Virginia, and the United States House of Representatives.
[9] DFCR's first major coverage came in April 2016 by The Washington Post where it made a notable break from other medical professional organizations by endorsing the legalization of cannabis for adult consumption, arguing that prohibition does far more harm to the public than good.
The resulting commission report cited DFCR's Declaration of Principles and found that regulating cannabis "reduces risks and improves quality control and consumer protection.
[15] As part of its initiative, DFCR worked with former NFL running back Mike James to file the first therapeutic use exemption with the league in May 2018, though it was ultimately denied.